{
  "ticker": "GH",
  "content": "**Report Generated:** January 27, 2026  \n**Next Refresh:** April 28, 2026\n\n**Disclaimer:** This sell-side report was generated using Claude Sonnet 4 (claude-sonnet-4-20250514). Please confirm all critical data independently, as AI models may hallucinate. These reports are for educational purposes only, and should not be solely used for investment decisions.\n\n---\n\n# Guardant Health (GH) - Comprehensive Analysis Report\n\n## 1. Company Overview\n\nGuardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company engages in the provision of treatment of cancer through the use of proprietary blood-based tests, vast data sets, and advanced analytics. Founded by Helmy Eltoukhy, AmirAli H. Talasaz, and Michael Joseph Wiley in December 2011 and headquartered in Palo Alto, CA.\n\nGuardant Health is a precision oncology company focused on guarding wellness and giving every person more time free from cancer. It provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. The company's mission revolves around conquering cancer through data-driven precision oncology solutions that improve patient outcomes across all stages of cancer care.\n\nGuardant Health is a leader in liquid biopsy. It has market-leading platforms in genomics profiling, molecular residual disease, or MRD, testing, and single cancer screening for colorectal cancer. With over 500,000 of blood tests performed by 12,000 doctors to date, the company's commercially available tests help inform treatment decisions for patients by holding insights that can improve clinical outcomes.\n\n## 2. Current Market Data\n\nWith a market cap of $14.86B, Guardant Health (GH) trades at $114.86. Over the past 52 weeks, Guardant Health (GH) stock has traded between a high of $120.74 and a low of $34.88. Trading volume for Guardant Health (GH) stock has reached 570.76K, versus its average volume of 2M.\n\nGuardant Health is going to release the next earnings report on Feb 19, 2026. GH earnings for the last quarter are −$0.74 USD per share, whereas the estimation was −$0.79 USD resulting in a 6.28% surprise. EBITDA is −$402.32M USD, and current EBITDA margin is −54.29%. As of Jan 26, 2026, the company has 2.02K employees.\n\n## 3. Existing Products/Services\n\n### Core Oncology Portfolio\nThe company provides precision oncology testing services comprising Guardant360, a panel of genetic tests; Guardant360 LDT that measures 730+ genes and supports all guideline-recommended biomarkers; Guardant360 CDx Test, a liquid biopsy test; Guardant360 Response Test, a blood-only liquid biopsy; Guardant360 TissueNext Test, a tissue-based test with AI-powered PD-L1 detection; GuardantINFINITY Test that provides insights into the complexities of tumor molecular profiles and immune response to advance cancer research and therapy development; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI blood test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.\n\n### Shield Test\nShield is the first and only blood test to receive full FDA approval as a primary screening option for colorectal cancer in average-risk adults aged 45 and older. Since its commercial launch as a laboratory-developed test (LDT) in May 2022, adherence rates have exceeded 90%, indicating high patient compliance.\n\n### Additional Tests\nIt also offers Shield Test; Guardant Reveal Test for adjuvant treatment and surveillance settings in early-stage cancer patients; and Smart Liquid Biopsy Platform.\n\n## 4. Planned Products/Services/Projects\n\nGuardant Health (Nasdaq: GH) expanded its tissue-free Guardant Reveal blood test on November 10, 2025 to include late-stage therapy response monitoring for patients with solid tumors. \n\nThe company has expanded Shield to include multi-cancer detection findings, further enhancing the clinical value of the platform for both patients and physicians.\n\nReveal Ultra development is progressing. Reveal: Submitted packages for breast cancer reimbursement and monitoring for IO and chemotherapy.\n\n## 5. Growth Strategy\n\nSales Force: Increased from 100 to over 250 reps this year, with plans to reach 600-700. The company is expanding commercial channels through internal efforts and partnership opportunities which are going to go live early 2026. Partnership with Quest not only would give access to their nationwide channel, but very importantly on the EMR integration side. They are fast-forwarding their EMR strategy by many years.\n\nThe company remains confident in the potential inclusion of Shield in the American Cancer Society guidelines in the near future which should be a catalyst for broader patient access.\n\n## 6. Current and Potential Major Clients\n\n### Strategic Partnerships\n\n**Quest Diagnostics Partnership:**\nThrough a multi-year agreement, Quest's provider clients that order lab testing from Quest will be able to directly order Shield through their existing Quest account and electronic health record (EHR). Quest's provider clients will also be able to refer patients to Quest's 2,000 patient service centers and 6,000 in-office phlebotomists for blood draws in the United States. In addition, Quest's national commercial sales team will proactively educate primary care physicians and obstetricians and gynecologists about the test, accelerating awareness among Quest's ordering providers. Quest provided healthcare connectivity solutions to approximately 650,000 clinician and hospital accounts last year.\n\n**Major Pharmaceutical Partnerships:**\nGuardant Health announced a multi-year collaboration with Merck, known as MSD outside the United States and Canada, to support the development and commercialization of Merck's oncology portfolio using the Guardant Infinity Smart platform.\n\nGuardant Health announced a strategic collaboration with Pfizer, Inc. to support the development and commercialization of Pfizer's oncology portfolio using the Guardant Infinity smart liquid biopsy platform.\n\n**Healthcare System Partnerships:**\nAnnounced collaborations with Quest Diagnostics and PATH Group (expanding Shield access to 250+ health systems in 25 states).\n\n**Government Coverage:**\nShield blood test for colorectal cancer screening is now covered for active-duty service members and their families through TRICARE, the U.S. military's health insurance coverage, with no copay for average-risk individuals ages 45 and older. According to the Department of Defense, there are approximately 1.3 million active-duty service members.\n\n## 7. Financial Data & Performance\n\n### Recent Financial Results\nFourth quarter 2025 preliminary unaudited financial results: Total revenue of approximately $280 million, an increase of 39%. Reported approximately 79,000 oncology tests, an increase of 38%. Reported approximately 38,000 Shield screening tests, compared to 6,400 tests in the prior year period.\n\nFull year 2025 preliminary unaudited financial results: Total revenue of approximately $981 million, an increase of 33%. Reported approximately 276,000 oncology tests, an increase of 34%. Reported approximately 87,000 Shield screening tests.\n\nShield testing revenue reached $24 million in Q3, driven by 24,000 tests and ASPs close to $900, with strong adherence rates.\n\nPreliminary unaudited free cash flow was approximately negative $54 million for the fourth quarter of 2025, and approximately negative $233 million for the full year 2025. Cash, cash equivalents, restricted cash, and marketable debt securities were approximately $1.3 billion as of December 31, 2025.\n\n## 8. Headwinds & Tailwinds\n\n### Tailwinds\n- **FDA Approval for Shield:** The move marks the first time a blood test has been approved by the FDA for CRC screening. The approval allows healthcare providers to offer Shield as a primary screening method, similar to other non-invasive options.\n- **Reimbursement Progress:** The Shield test will be reimbursed at the amount of $1,495 for Medicare patients during the initial nine-month ADLT period beginning April 1, 2025. During the initial ADLT period, Guardant Health will collect, assess and submit private-payer payment rate data for the test, the median of which will be used by CMS to determine the Medicare pricing, beginning January 1, 2026.\n- **Strong Market Position:** Guardant is a leader in liquid biopsy and has been a step ahead of the competition, which could eventually enable it to secure a lasting first-mover advantage with its Shield test.\n\n### Headwinds\n- **Profitability Challenges:** EBITDA is −$402.32M USD, and current EBITDA margin is −54.29%.\n- **Cash Burn:** Preliminary unaudited free cash flow was approximately negative $233 million for the full year 2025.\n- **Competition:** The liquid biopsy market is fragmented with numerous competitors developing similar technologies.\n\n## 9. Market Shares\n\nThe top five players in the liquid biopsy market are Natera, Inc. (US), Guardant Health (US), Myriad Genetics, Inc. (US), Illumina, Inc. (US), and F. Hoffmann-La Roche Ltd. (Switzerland).\n\nLeading companies include: F. Hoffmann-La Roche AG (5%), Thermo Fisher Scientific Inc (3%), Guardant Health Inc (3%), Illumina Inc (3%), Exact Sciences Corporation (2%), Natera Inc (2%). The market is fragmented, with the top 10 players accounting for 24% of total market revenue in 2023.\n\nThe liquid biopsy market is projected to reach USD $7.05 billion by 2030 from USD $4.03 billion in 2025, at a CAGR of 11.8% during the forecast period.\n\n## 10. Comparison to Competitors\n\nGuardant Health operates a vertically integrated model, combining test development, bioinformatics, and commercial partnerships to advance blood-based cancer diagnostics across multiple stages of care.\n\nKey competitors include:\n- **Natera Inc.:** Plays a key role in the liquid biopsy market with its service-based model, offering clinically validated oncology and organ transplant care tests.\n- **Exact Sciences:** Other products for colorectal cancer detection include Guardant Health's Shield and Reveal systems, as well as Exact Sciences' Cologuard.\n- **GRAIL:** The only liquid biopsy that can screen for lung cancer is Galleri, a pan-cancer screen launched by Illumina's subsidiary Grail.\n\n## 11. Partnerships, Mergers and Acquisitions\n\n### Recent Strategic Partnerships (2025-2026)\nGuardant Health announced a strategic collaboration with Trial Library on December 11, 2025 to expand access to oncology clinical trials across the U.S. The partnership pairs Guardant's real-world genomic dataset of more than 1 million patients tested with Trial Library's AI matching and navigation platform active in 320+ clinics and with 1,500 providers.\n\nGuardant Health announced on December 9, 2025 the launch of FPG 360, an in-house liquid biopsy testing service at Fondazione Policlinico Universitario Agostino Gemelli IRCCS in Rome, Italy. The collaboration is described as one of the first dedicated hospital-based liquid biopsy facilities in Italy and follows Guardant Health partnerships with Val d'Hebron/VHIO and The Royal Marsden.\n\n## 12. Recent Developments\n\n### January 2026\nGuardant Health receives FDA approval for Guardant360 CDx in colorectal cancer on January 22, 2026.\n\nGuardant Health announced its Shield blood test for colorectal cancer screening is now covered for active-duty service members and their families through TRICARE, the U.S. military's health insurance coverage, with no copay for average-risk individuals ages 45 and older.\n\n### 2025 Key Developments\nIn January 2026, Guardant Health reported unaudited revenue of approximately US$280 million for Q4 and US$981 million for 2025, reflecting strong year-on-year growth across its oncology and Shield colorectal cancer screening tests.\n\nIn December 2022, Guardant Health partnered with Susan G. Komen to conduct clinical studies for identifying early-stage breast cancer patients with the help of Guardant Reveal, a blood-based test.\n\n## 13. AI Investment Rating & Fair Value Assessment\n\n**Buy Rating: 7.8/10**\n\n### Investment Thesis\nGuardant Health represents a compelling growth opportunity in the rapidly expanding liquid biopsy market. The company has achieved several significant milestones that position it for strong growth:\n\n**Strengths:**\n- First-mover advantage with FDA-approved blood-based colorectal cancer screening\n- Strong financial momentum with 39% Q4 2025 revenue growth\n- Robust partnerships with major healthcare providers (Quest) and pharmaceutical companies (Merck, Pfizer)\n- Expanding market opportunity with Shield multi-cancer detection capabilities\n- Strong cash position of $1.3 billion providing runway for continued investment\n\n**Growth Catalysts:**\n- Most recent consensus from 22 analysts is for revenues of US$1.22b in 2026. If met, it would imply a substantial 35% increase on its revenue over the past 12 months.\n- Potential inclusion of Shield in the American Cancer Society guidelines should be a catalyst for broader patient access.\n- Expanding sales force and distribution channels through strategic partnerships\n\n**Risk Factors:**\n- Current unprofitability with negative EBITDA margins\n- Significant cash burn requiring path to profitability\n- Competitive market with fragmented landscape\n\n### Fair Value Estimate: $135-$145\n\nSimply Wall St analysis shows Guardant Health's forecasts yield a $118.18 fair value, a 6% upside to its current price. However, considering the company's strong revenue growth trajectory, expanding market opportunity, and strategic partnerships, our analysis suggests a fair value range of $135-$145 per share, representing approximately 17-26% upside from current levels.\n\nThe valuation is supported by:\n- Strong revenue growth expectations of 35% in 2026\n- Expanding TAM in liquid biopsy market ($7.05B by 2030)\n- First-mover advantage in blood-based cancer screening\n- Strategic positioning for long-term market leadership",
  "generated_date": "2026-01-27T07:36:05.566844",
  "next_refresh_date": "2026-04-28T07:36:05.566844",
  "model": "claude-sonnet-4-20250514",
  "cost": 0.3157623,
  "tokens": {
    "input": 183,
    "output": 4726,
    "cache_creation": 54422,
    "cache_read": 134136
  },
  "tldr_summary": "Guardant Health is a precision oncology company pioneering blood-based cancer testing and screening technologies, with a focus on advanced genomic profiling and early cancer detection.\n\nKey highlights include FDA approval for Shield, the first blood test for colorectal cancer screening, and strategic partnerships with Quest Diagnostics, Merck, and Pfizer. The company leads the liquid biopsy market with innovative tests like Guardant360 and Shield, serving over 12,000 doctors and performing 500,000+ blood tests. With 39% Q4 2025 revenue growth and expanding into multi-cancer detection, Guardant is positioning itself as a market leader. The company has strong tailwinds from FDA approvals, reimbursement progress, and growing market opportunity, though it currently faces profitability challenges with negative EBITDA margins.\n\nThe AI analysis provides a \"Buy\" rating of 7.8/10, with a fair value estimate of $135-$145, representing a 17-26% potential upside based on strong revenue growth and strategic market positioning."
}